Gilead's Kite Presents Results From Pivotal ZUMA-2 Trial In Relapsed Or Refractory Mantle Cell Lymphoma; Results Showed 93 Percent of Patients Treated With Investigational KTE-X19 Achieved Response
Benzinga Newsdesk